For patients with adenocarcinoma of the esophagus and esophagogastric junction, chemoradiotherapy and chemotherapy improved ...

Recent clinical research from BGI Genomics and Zhongshan Hospital, Fudan University, highlights the effectiveness of ...

Lucid Diagnostics, a subsidiary of PAVmed Inc . (NASDAQ:PAVM), is dedicated to the early detection and prevention of esophageal cancer. The company's products, including the EsoGuard test ...

Tobacco, obesity and sun exposure are the risk factors we've been told time and time again can cause cancer, but something ...

PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating ...

FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to ...

is a risk factor for esophageal cancer. Barrett's esophagus is caused by gastroesophageal reflux disease (GERD), which occurs when stomach acid repeatedly flows back into the esophagus ...

Jeff Pinski, 79, was at higher risk of throat cancer due to Barrett's esophagus. He previously battled skin, bladder and ...

Spatial dynamics of CD39 + CD8 + exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer Immune checkpoint blockade (ICB) benefits esophageal ...

Spatial dynamics of CD39 + CD8 + exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer Immune checkpoint blockade (ICB) benefits esophageal ...

Esophageal cancer is associated with an overall five-year survival rate of around 20%, according to the American Cancer Society. That rate significantly increases the earlier the disease is caught ...